The 2026 Taiwan headache society guideline on the use of treatments targeting the CGRP pathway
Year: 2026
Type: article
Abstract: The introduction of CGRP-targeted therapy has markedly influenced migraine care in Taiwan, together with accumulating evidence and clinical experience. Therefore, the Treatment Guideline Subcommittee of the Taiwan Headache Society updated its 2022 consensus on preventive migraine therapy, with a specific focus on CGRP-targeted therapies. This updated guideline also provides evidence-based recommendations and practical guidance on the use of gepants following their introduction in Taiwan. After reviewing recent clinical trials, meta-analyses, and international guidelines, and integrating expert panel opinions, we developed this new guideline to update the treatment options, recommended populations, timing of initiation and discontinuation, and practical considerations for CGRP-targeted therapy, organised into ten clinical questions. According to the current consensus, preventive treatment is recommended for patients with ≥4 headache days per month, significant disability, failure of or contraindications to acute therapy, complicated migraine with severe aura (such as hemiplegic migraine or migrainous infarction), or when patient preference favours prevention after balancing potential benefits and risks. Currently, CGRP-targeted therapies for migraine prevention include anti-CGRP monoclonal antibodies, namely erenumab, fremanezumab, galcanezumab, and eptinezumab, as well as small-molecule CGRP receptor antagonists, including rimegepant and atogepant. In this 2026 updated guideline, CGRP-targeted therapy is listed as one of the first-line treatment options for both episodic and chronic migraine prevention. A history of failure of multiple preventive medications is not required before initiating CGRP-targeted therapy, as early initiation may provide better migraine control than delayed treatment. For both episodic and chronic migraine, the Taiwan Headache Society recommends that CGRP-targeted therapy may be continued for up to 12 months. This update is crucial for improving migraine care and highlights the importance of continuous CGRP-targeted therapy, rather than premature or unnecessary treatment interruption.
Authors: Jr-Wei Wu, Yen-Feng Wang, Wei-Ta Chen, Tsung-Wei Hou, Yi-Chia Liaw, Yi-Hsien Tu, Chi Ieong Lau, Ping-Kun Chen, Shih-Pin Chen, Wei-Hung Chen, Yen-Yu Chen, Jong-Ling Fuh, Yung-Chu Hsu, Tzu-Chou Huang, Tzu-Hsien Lai, Jen-Feng Liang, Kang-Hsu Lin, Kao-Chang Lin, Ching-Sen Shih, Shuu-Jiun Wang, Chun Ming Yang, Fu-Chi Yang, Tu-Hsueh Yeh, Chun-Pai Yang
Institutions: National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Taichung Veterans General Hospital, China Medical University, An-Nan Hospital, Fu Jen Catholic University, Shin Kong WHS Memorial Hospital, University College London, China Medical University Hospital, Changhua Christian Hospital, Asia Eastern University of Science and Technology, Far Eastern Memorial Hospital, Chi Mei Medical Center, Kaohsiung Veterans General Hospital, Tri-Service General Hospital, National Defense Medical Center, Taipei Medical University Hospital, Taipei Medical University, National Chung Hsing University, Kuang Tien General Hospital
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7226035875
